At this time, Tabloid (thioguanine) tablets are available in brand-name form only. Although there are no patents or exclusivity rights preventing a company from making a generic version of this drug, no generic Tabloid is currently available. This may be because the demand for the drug is too small for it to be profitable to make a generic version.
Tabloid® (thioguanine) is a prescription medication approved to treat acute nonlymphocytic leukemia (more commonly known as acute myeloid leukemia), a type of cancer of the blood and bone marrow. It belongs to a group of medicines known as purine analogs.
Tabloid is made by DSM Pharmaceuticals, Inc., for GlaxoSmithKline. Although it is no longer protected from generic competition by patents, it is not yet available as a generic medication.
Tabloid was approved by the U.S. Food and Drug Administration (FDA) prior to 1982, and is not protected from generic competition by patents or exclusivity rights. Normally, generic manufacturers will make generic versions of medicines that are no longer protected by patents. However, no manufacturer has chosen to make a generic version of Tabloid at this time.
It is not entirely clear why a generic version of this drug is not being made. It could be that the demand for the medicine is too small for a generic manufacturer to profit from making a generic version. Because it is unclear why a manufacturer has not chosen to make a generic form of Tabloid, it is difficult to predict when, or even if, a generic version will become available.
No -- thioguanine is the active ingredient in Tabloid, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent, and another company besides the original manufacturer must make the product.